Axsome Therapeutics
AXSM
172.97
-1.37
-0.79%
Axsome Therapeutics
US · AXSM
#1533 by market cap
Listed 2015
172.97
-1.37
-0.79%
Live - 5344 symbols - heartbeat 205s ago
· 2026-10-08 08:26
Pre-market
173.50
+0.31%
After-hours
172.97
0.00%
Overnight
172.59
-0.22%
- Market cap
- 9.06B
- P/E (TTM)i
- -46.13
- P/Bi
- 108.79
- EPSi
- -3.68
- Div yieldi
- 0.00%
- 52W posi
- 38%
Reader sentiment
Are you bullish or bearish on AXSM?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 6.87, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +65.55% YoY
Margins
- Gross margin
- 92.56%
- Operating margin
- -26.51%
- Net margin
- -28.69%
Key ratios & quality
- Enterprise valuei
- 8.93B
- Altman Z-Scorei
- 6.87
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -- | -- | 0 | 0 | 50.04M | 270.60M | 385.69M | 638.50M |
| Gross profit | -- | -- | 0 | 0 | 44.84M | 244.54M | 352.39M | 591.02M |
| Selling & admin expenses | 9.35M | 13.60M | 28.90M | 66.65M | 159.25M | 323.12M | 411.36M | 570.60M |
| Research & development | 23.50M | 53.65M | 70.24M | 58.06M | 57.95M | 97.94M | 187.08M | 183.28M |
| Operating profit | -32.63M | -67.11M | -99.09M | -124.71M | -176.50M | -182.91M | -252.44M | -169.24M |
| Pretax profit | -30.97M | -68.35M | -102.90M | -130.40M | -187.13M | -238.28M | -287.13M | -183.70M |
| Tax | -- | -- | -- | 0 | 0 | 960.00K | 85.00K | -530.00K |
| Net profit | -30.97M | -68.35M | -102.90M | -130.40M | -187.13M | -239.24M | -287.22M | -183.17M |
| Basic EPS | -1 | -2 | -3 | -3 | -5 | -5 | -6 | -4 |
| Diluted EPS | -1.15 | -2.01 | -2.77 | -3.47 | -4.60 | -5.27 | -5.99 | -3.68 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 121.46M | 150.04M | 170.99M | 196.00M | 191.20M | 218.38M |
| Gross profit | 111.67M | 136.59M | 159.08M | 183.67M | 176.48M | 204.81M |
| Selling & admin expenses | 120.79M | 130.28M | 150.24M | 169.30M | 185.00M | 208.14M |
| Research & development | 44.79M | 49.54M | 40.16M | 48.79M | 52.68M | 46.23M |
| Operating profit | -55.47M | -44.82M | -32.92M | -36.03M | -62.77M | -51.14M |
| Pretax profit | -59.41M | -48.93M | -47.23M | -28.13M | -64.54M | -51.19M |
| Tax | 0 | -960.00K | 0 | 430.00K | 0 | 128.00K |
| Net profit | -59.41M | -47.97M | -47.23M | -28.56M | -64.54M | -51.31M |
| Basic EPS | -1 | -1 | -1 | -1 | -1 | -1 |
| Diluted EPS | -1.22 | -0.97 | -0.94 | -0.56 | -1.26 | -0.99 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 15.22M | 220.38M | 184.02M | 86.52M | 245.64M | 504.26M | 485.06M | 588.99M |
| Cash & ST investments | 13.97M | 219.97M | 183.88M | 86.47M | 200.84M | 386.19M | 315.35M | 322.93M |
| Inventory | -- | -- | -- | 0 | 4.32M | 15.14M | 15.73M | 27.94M |
| Total assets | 15.38M | 220.55M | 186.13M | 87.79M | 331.48M | 588.24M | 568.50M | 689.81M |
| Total current liabilities | 10.82M | 24.49M | 23.44M | 23.07M | 96.56M | 138.85M | 230.10M | 378.84M |
| Short-term debt | 3.29M | 2.60M | 1.22M | 620.68K | 425.00K | 1.27M | 3.26M | 72.98M |
| Long-term debt | 3.62M | 17.33M | 48.32M | 49.09M | 94.26M | 178.07M | 180.71M | 117.75M |
| Total liabilities | 14,441,358.00 | 41,827,371.00 | 72,341,414.00 | 72,154,706.00 | 221,920,000.00 | 397,259,000.00 | 511,483,000.00 | 601,510,000.00 |
| Total equity | 937.92K | 178.72M | 113.79M | 15.63M | 109.56M | 190.98M | 57.02M | 88.30M |
| Retained earnings | -107.55M | -175.90M | -278.80M | -409.20M | -596.33M | -835.57M | -1.12B | -1.31B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 494.63M | 536.62M | 565.34M | 588.99M | 611.21M | 656.57M |
| Cash & ST investments | 300.91M | 303.02M | 325.27M | 322.93M | 305.11M | 319.85M |
| Inventory | 16.32M | 18.44M | 23.77M | 27.94M | 31.52M | 37.88M |
| Total assets | 596.67M | 639.79M | 669.25M | 689.81M | 713.61M | 761.45M |
| Total current liabilities | 243.91M | 342.10M | 360.29M | 378.84M | 439.21M | 460.45M |
| Short-term debt | 2.27M | 72.35M | 73.23M | 72.98M | 73.82M | 76.13M |
| Long-term debt | 181.38M | 117.54M | 117.64M | 117.75M | 117.85M | 117.96M |
| Total liabilities | 543,466,000.00 | 566,710,000.00 | 595,523,000.00 | 601,510,000.00 | 659,020,000.00 | 678,143,000.00 |
| Total equity | 53.21M | 73.08M | 73.73M | 88.30M | 54.59M | 83.30M |
| Retained earnings | -1.18B | -1.23B | -1.28B | -1.31B | -1.37B | -1.42B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -30.05M | -46.38M | -78.46M | -108.23M | -116.51M | -145.08M | -128.41M | -93.41M |
| Depreciation & amortization | 48.94K | 37.33K | 77.72K | 76.00K | 4.40M | 6.83M | 7.96M | 9.06M |
| Free cash flow | -30.09M | -46.39M | -78.50M | -108.53M | -117.21M | -145.66M | -128.68M | -93.89M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 12.88M | 238.23M | 14.13M | 7.44M | 243.76M | 258.75M | 40.78M | 67.90M |
| Ending cash balance | 13.97M | 219.97M | 183.88M | 86.47M | 200.84M | 386.19M | 315.35M | 322.93M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -43.38M | -32.42M | 1.05M | -18.65M | -20.70M | -32.95M |
| Depreciation & amortization | 2.13M | 2.25M | 2.41M | 2.27M | 2.37M | 2.89M |
| Free cash flow | -43.71M | -32.44M | 988.00K | -18.72M | -20.82M | -33.40M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 19.65M | 32.63M | 9.95M | 5.68M | 6.34M | 13.47M |
| Ending cash balance | 300.91M | 303.02M | 325.27M | 322.93M | 305.11M | 319.85M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -350.78 | -76.08 | -70.36 | -201.51 | -298.97 | -159.21 | -231.63 | -252.11 |
| ROA %i | -121.59 | -57.94 | -50.60 | -95.21 | -89.27 | -52.02 | -49.66 | -29.11 |
| ROIC %i | -172.98 | -64.99 | -55.35 | -108.79 | -133.39 | -80.52 | -89.48 | -63.50 |
| 5-year avg ROE %i | -- | -142.90 | -145.68 | -169.98 | -199.54 | -161.23 | -192.34 | -228.69 |
| EBIT margin %i | -- | -- | -- | -- | -359.33 | -85.67 | -72.74 | -27.74 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 1.41 | 9.00 | 7.85 | 3.75 | 2.54 | 3.63 | 2.11 | 1.55 |
| Quick ratioi | 1.29 | 8.98 | 7.85 | 3.75 | 2.47 | 3.46 | 1.99 | 1.44 |
| Debt / assetsi | 44.94 | 9.04 | 26.93 | 56.63 | 28.56 | 31.68 | 33.94 | 31.62 |
| LT debt / equityi | 385.90 | 9.70 | 42.98 | 314.07 | 86.04 | 96.93 | 332.72 | 164.37 |
| Interest coveragei | -26.47 | -54.14 | -39.10 | -21.89 | -24.51 | -35.93 | -42.71 | -27.02 |
| Revenue CAGR (3Y) %i | 0.00 | 0.00 | 0.00 | 0.00 | -- | -- | -- | 133.68 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -282.16 | -280.68 | -275.50 | -252.11 | -349.38 | -245.10 |
| ROA %i | -48.72 | -41.57 | -37.30 | -29.11 | -28.74 | -27.35 |
| ROIC %i | -90.99 | -81.53 | -76.87 | -63.50 | -67.92 | -63.05 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -62.54 | -48.34 | -39.70 | -27.74 | -25.91 | -23.96 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 2.03 | 1.57 | 1.57 | 1.55 | 1.39 | 1.43 |
| Quick ratioi | 1.90 | 1.47 | 1.45 | 1.44 | 1.27 | 1.30 |
| Debt / assetsi | 35.40 | 33.97 | 32.66 | 31.62 | 30.82 | 29.51 |
| LT debt / equityi | 392.75 | 198.37 | 197.16 | 164.37 | 267.61 | 178.34 |
| Interest coveragei | -34.13 | -28.31 | -29.34 | -27.02 | -34.56 | -37.09 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- AUVELITY is the largest reported line at 82.56% of revenue, across 5 reported segments.
- The next-largest line, Sunosi, is a distant second at 15.49% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
AUVELITY82.56%
Sunosi15.49%
Symbravo1.03%
SUNOSI royalty revenue0.67%
SUNOSI milestone revenue0.25%
Quote time 2026-10-08 08:26:21 · For reference only, not investment advice and not tailored to your situation.